Indivior PLC (NASDAQ:INDV) Stock Has Consensus Price Target of $45.17 According to Analysts

Shares of Indivior PLC (NASDAQ:INDV) have earned an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $45.17.

Several brokerages recently weighed in on INDV. Barclays dropped their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. Craig Hallum reissued a “buy” rating and issued a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. Finally, Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th.

Indivior Trading Up 0.1%

Indivior stock opened at $34.79 on Thursday. Indivior has a 1-year low of $24.03 and a 1-year high of $42.81. The firm has a market capitalization of $4.11 billion, a PE ratio of 12.47 and a beta of 0.87. The firm’s 50 day simple moving average is $35.66 and its 200 day simple moving average is $36.86.

Indivior (NASDAQ:INDV) last announced its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The business had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. Research analysts forecast that Indivior will post 3.66 earnings per share for the current year.

Indivior Dividend Announcement

The firm also recently declared a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be issued a dividend of $8.13 per share.

Insider Buying and Selling at Indivior

In other Indivior news, CAO Woodrow D. Anderson purchased 1,500 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were acquired at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the transaction, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC bought a new position in shares of Indivior during the 2nd quarter valued at about $3,409,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Indivior during the second quarter valued at $7,988,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Indivior in the 2nd quarter worth $3,332,000. Cookson Peirce & Co. Inc. bought a new position in shares of Indivior in the 2nd quarter valued at about $1,390,000. Finally, Wellington Management Group LLP bought a new stake in shares of Indivior in the 2nd quarter worth about $1,870,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.